<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835496</url>
  </required_header>
  <id_info>
    <org_study_id>LA41-0412</org_study_id>
    <nct_id>NCT01835496</nct_id>
  </id_info>
  <brief_title>Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease</brief_title>
  <official_title>The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetics of deferiprone and its
      3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in
      patients with sickle cell disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, single-dose study of Ferriprox in patients with sickle cell disease.
      Patients found to be eligible will visit the clinic the day before receiving the drug, in
      order to reconfirm eligibility and to undergo baseline assessments, and will receive a single
      dose of 1500 mg Ferriprox under fasting conditions. Blood and urine samples for
      pharmacokinetic assessment will be collected over a 10-hour period. Standard safety
      assessments will be performed throughout the study, and patients will return for a safety
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>10-hour interval</time_frame>
    <description>Cmax (maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>10-hour interval</time_frame>
    <description>Tmax (time to the maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.
The results of the Tmax parameter are reported as the median and range (other parameters are reported as mean and standard deviation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>10-hour interval</time_frame>
    <description>AUC0-∞ (area under the curve, zero to infinity) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>10-hour interval</time_frame>
    <description>T1/2 (apparent terminal elimination half-life) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>From Day 1 (Dosing) to Day 7 plus/minus 3 days (Follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events</measure>
    <time_frame>From Day 1 (Dosing) to Day 30 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Ferriprox</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>single 1500 mg dose of Ferriprox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single 1500 mg dose of Ferriprox</intervention_name>
    <description>A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions</description>
    <arm_group_label>Ferriprox</arm_group_label>
    <other_name>deferiprone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18-45 years of age (inclusive)

          2. Diagnosis of sickle cell disease, confirmed by Hb electrophoresis

          3. Body weight ≥ 50 kg

          4. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m^2

          5. Absolute neutrophil count (ANC) of &gt;1.5 x 10^9/L

          6. Women of childbearing potential must agree to either be sexually inactive or use an
             acceptable method of birth control for 14 days prior to dosing and for 30 days
             afterwards

          7. A fertile heterosexual male must agree that he or his partner will use an effective
             method of contraception for 14 days prior to dosing and for 30 days afterwards

        Exclusion Criteria:

          1. History or presence of hypersensitivity or idiosyncratic reaction to Ferriprox

          2. Use of Ferriprox within the past 3 months

          3. History of malignancy

          4. Evidence of abnormal liver function (serum Alanine Transaminase (ALT)level &gt; 5 times
             upper limit of normal or creatinine levels &gt;2 times upper limit of normal)

          5. A serious, unstable illness, as judged by the Investigator, within the past 3 months
             before screening visit including but not limited to hepatic, renal,
             gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or
             immunologic disease

          6. Hemodialysis during the week prior to dosing or planned for the day of dosing

          7. Known difficulty in providing blood samples

          8. Disorders or surgery of the gastrointestinal tract that may interfere with drug
             absorption or may otherwise influence the Pharmacokinetic (PK) results (e.g.,
             resection of the small or large intestine, febrile conditions, chronic diarrhea,
             chronic vomiting, endocrine disease, severe infections, acute inflammations, etc.)

          9. Clinically significant abnormalities on 12-lead ECG (e.g., QT interval corrected using
             Fridericia's formula (QTcF) ≥ 430 ms in males or ≥ 450 ms in females)

         10. Use of tobacco/nicotine-containing products for at least 3 months prior to study drug
             administration

         11. Use of any drugs within the past 14 days that are metabolized by the Uridine
             diphosphate glucosyltransferase enzyme (UGT1A6) and hence could affect the PK of
             Ferriprox

         12. Treatment with an investigational drug within the past 30 days or 5 half-lives of that
             drug (whichever is longer) prior to study drug administration

         13. Pregnant or nursing female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Soulieres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM - Hôpital Notre-Dame</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUM-Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>iron overload</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Ferriprox</keyword>
  <keyword>deferiprone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ferriprox</title>
          <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferriprox</title>
          <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>Cmax (maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
        <time_frame>10-hour interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>Cmax (maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.56" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.95" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events</title>
        <time_frame>From Day 1 (Dosing) to Day 7 plus/minus 3 days (Follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Serious Adverse Events</title>
        <time_frame>From Day 1 (Dosing) to Day 30 post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Serious Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>Tmax (time to the maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.
The results of the Tmax parameter are reported as the median and range (other parameters are reported as mean and standard deviation).</description>
        <time_frame>10-hour interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>Tmax (time to the maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.
The results of the Tmax parameter are reported as the median and range (other parameters are reported as mean and standard deviation).</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax for serum seferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.50" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.750" lower_limit="1.33" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>AUC0-∞ (area under the curve, zero to infinity) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
        <time_frame>10-hour interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>AUC0-∞ (area under the curve, zero to infinity) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞ for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.37" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-∞ for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.7" spread="47.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>T1/2 (apparent terminal elimination half-life) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
        <time_frame>10-hour interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox</title>
            <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>T1/2 (apparent terminal elimination half-life) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.458" spread="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of dosing to 7 ±3 days post-dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ferriprox</title>
          <description>A single dose of 1500 mg of Ferriprox (three 500 mg tablets) administered under fasting conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All unpublished information given to the PI by ApoPharma shall not be published or disclosed to a third party without the prior written consent of ApoPharma.
The data generated by this study are considered confidential information and the property of ApoPharma. This confidential information may be published only in collaboration with participating personnel from ApoPharma or upon ApoPharma written consent to publish the article.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Fradette, PhD</name_or_title>
      <organization>ApoPharma Inc.</organization>
      <phone>416-401-7543</phone>
      <email>cfradett@apopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

